Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Dec 13, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at ways to prevent and reduce the side effects of radiation therapy that can affect the esophagus, a condition known as radiation esophagitis. Researchers want to find out what symptoms patients experience during treatment and if there is any noticeable weight loss among participants. The goal is to improve comfort and health for those receiving thoracic radiation therapy.

To be eligible for the study, participants need to be 18 years or older and undergoing thoracic radiation with specific dosage criteria related to the esophagus. For instance, they must have a certain level of radiation exposure to the esophagus. However, individuals who cannot take a medication called Sucralfate, have a feeding tube, are taking opioid pain medications before starting radiation, or have a history of opioid use disorder are not eligible. If you participate, you can expect to share your experiences and symptoms during treatment, which will help researchers learn more about managing these side effects in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients being treated with thoracic irradiation with high-risk esophageal dose as determined below:
• Esophageal dose:
• • V50 ≥ 15% (25-35 once daily fractions) or 40 twice-daily \[BID\] fractions)
• • V40 ≥ 15% (15-24 once daily fractions or 30 twice-daily \[BID\] fractions)
• • V30 ≥ 15% (10-14 once daily fractions)
• • Age 18 years of age or older.
• Exclusion Criteria:
• • Known inability to take Sucralfate (tablet and/or suspension form), per physician discretion
• • PEG tube
• • Actively taking any opioid pain medications prior to radiation therapy
• • History of an opioid use disorder

Trial Officials